Condition
Essential Fatty Acid Deficiency (EFAD)
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
100%
3 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
3Total
P 4 (3)
Trial Status
Completed1
Recruiting1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06049680Phase 4Recruiting
Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients
NCT04555044Phase 4CompletedPrimary
Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)
NCT02476994Phase 4TerminatedPrimary
Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion
Showing all 3 trials